This clinical trial is focused on studying the effects of the 20-Valent pneumococcal conjugate vaccine (PCV-20) in adults who are at medium or high risk for pneumococcal infections. Pneumococcal infections are caused by bacteria that can lead to serious illnesses like pneumonia, meningitis, and bloodstream infections. The vaccine being tested, known as Prevenar 20, is designed to protect against 20 different types of these bacteria. The study aims to compare the immune response of patients who receive the vaccine during an acute febrile illness, which is a sudden fever, to those who receive it after their fever has resolved.
Participants in the study will be randomly assigned to one of two groups. One group will receive the vaccine while they are experiencing a fever, and the other group will receive it 15 to 58 days after their fever has subsided. The study will monitor the immune response of participants one month after vaccination to determine if the timing of the vaccine affects its effectiveness. The study will also track the safety of the vaccine by recording any side effects or reactions that occur within a month after vaccination.
In addition to the primary focus on immune response and safety, the study will also look at other factors over a year, such as the number of respiratory infections and confirmed Streptococcus pneumoniae infections in participants. The study will explore the diversity of gut bacteria and the presence of specific immune cells and antibodies related to the vaccine. This research will help determine the best timing for administering the PCV-20 vaccine to adults at risk for pneumococcal infections.
France 